Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Mayuresh M Abhyankar1, Barbara J Mann1, Jeffrey M Sturek2

  • 1Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.

NPJ Vaccines
|November 19, 2021
PubMed